Greig E, Rabiee R, Afshar A
Am J Ophthalmol Case Rep. 2024; 33:101987.
PMID: 38283770
PMC: 10818181.
DOI: 10.1016/j.ajoc.2023.101987.
Yousef Y, Al Jboor M, Mohammad M, Mehyar M, Toro M, Nazzal R
Front Pharmacol. 2021; 12:696787.
PMID: 34322023
PMC: 8311556.
DOI: 10.3389/fphar.2021.696787.
Yousef Y, Noureldin A, Sultan I, Deebajah R, Al-Hussaini M, Shawagfeh M
J Ophthalmol. 2020; 2020:8628525.
PMID: 32047663
PMC: 7003283.
DOI: 10.1155/2020/8628525.
Yu M, Dalvin L, Welch R, Shields C
Ocul Oncol Pathol. 2019; 5(4):284-289.
PMID: 31367592
PMC: 6615328.
DOI: 10.1159/000491432.
Francis J, Habib L, Abramson D
Adv Ophthalmol Optom. 2017; 2(1):177-195.
PMID: 29034355
PMC: 5635842.
DOI: 10.1016/j.yaoo.2017.03.008.
Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
Chao A, Kao L, Liu L, Wang N
BMC Ophthalmol. 2016; 16:27.
PMID: 26975871
PMC: 4791807.
DOI: 10.1186/s12886-016-0204-6.
Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma.
Francis J, Marr B, Brodie S, Abramson D
JAMA Ophthalmol. 2015; 133(12):1459-63.
PMID: 26378741
PMC: 4979541.
DOI: 10.1001/jamaophthalmol.2015.3119.
Investigating short-term toxicity of melphalan in a model of an isolated and superfused bovine retina.
Januschowski K, Krupp C, Mueller S, Hofmann K, Schnichels S, Hagemann U
Graefes Arch Clin Exp Ophthalmol. 2015; 254(1):91-6.
PMID: 26335534
DOI: 10.1007/s00417-015-3149-1.
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Pritchard E, Dyer M, Guy R
Mini Rev Med Chem. 2015; 16(6):430-54.
PMID: 26202204
PMC: 5509337.
DOI: 10.2174/1389557515666150722100610.
The role of intravitreal chemotherapy for retinoblastoma.
Manjandavida F, Shields C
Indian J Ophthalmol. 2015; 63(2):141-5.
PMID: 25827545
PMC: 4399123.
DOI: 10.4103/0301-4738.154390.
Intravitreal injection of melphalan for intraocular retinoblastoma.
Suzuki S, Aihara Y, Fujiwara M, Sano S, Kaneko A
Jpn J Ophthalmol. 2015; 59(3):164-72.
PMID: 25808017
DOI: 10.1007/s10384-015-0378-0.
Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013.
Munier F
Ophthalmic Genet. 2014; 35(4):193-207.
PMID: 25321846
PMC: 4245997.
DOI: 10.3109/13816810.2014.973045.
Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.
Francis J, Abramson D, Gobin Y, Marr B, Dunkel I, Riedel E
PLoS One. 2014; 9(1):e84247.
PMID: 24465398
PMC: 3896342.
DOI: 10.1371/journal.pone.0084247.
Pathological findings in enucleated eyes after intravitreal melphalan injection.
Ghassemi F, Amoli F
Int Ophthalmol. 2013; 34(3):533-40.
PMID: 24043335
DOI: 10.1007/s10792-013-9851-2.
Persistence of retinal function after intravitreal melphalan injection for retinoblastoma.
Brodie S, Munier F, Francis J, Marr B, Gobin Y, Abramson D
Doc Ophthalmol. 2012; 126(1):79-84.
PMID: 23143758
DOI: 10.1007/s10633-012-9358-6.
Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.
Shields C, Fulco E, Arias J, Alarcon C, Pellegrini M, Rishi P
Eye (Lond). 2012; 27(2):253-64.
PMID: 22995941
PMC: 3574237.
DOI: 10.1038/eye.2012.175.
Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma.
Graeber C, Gobin Y, Marr B, Dunkel I, Brodie S, Bornfeld N
Open Ophthalmol J. 2011; 5:1-5.
PMID: 21399766
PMC: 3052645.
DOI: 10.2174/1874364101105010001.
Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma.
Brodie S, Gobin Y, Dunkel I, Kim J, Abramson D
Doc Ophthalmol. 2009; 119(1):13-22.
PMID: 19169884
DOI: 10.1007/s10633-008-9164-3.
Effects of intraocular irrigation with melphalan on rabbit retinas during vitrectomy.
Shimoda Y, Hamano R, Ishihara K, Shimoda N, Hagimura N, Akiyama H
Graefes Arch Clin Exp Ophthalmol. 2007; 246(4):501-8.
PMID: 17934752
DOI: 10.1007/s00417-007-0685-3.
